Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Passage launches strategic review and 75% layoffs after gene therapy path blocked by FDA

Passage launches strategic review and 75% layoffs after gene therapy path blocked by FDA

  • May 4, 2026

After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic review and set out a plan to whittle down its headcount by 75%.

Leave A Comment

Fields (*) Mark are Required